December 27, 2024 10:48 AM ESTUpdated December 31, 10:39 AM
News Briefing

No­var­tis ends Phase 1 ra­dio­phar­ma tri­al; Solve Ther­a­peu­tics pur­sues $75M round

ENDPOINTS

No­var­tis ends a ra­dio­phar­ma tri­al with Pep­tiDream: The Swiss drug gi­ant ter­mi­nat­ed a Phase 1 tri­al of [177Lu]Lu-FF58 in pa­tients with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

A look at biotech's year of the megaround

GSK’s Nu­cala bags an­oth­er Chi­na ap­proval, but biggest test yet to come

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

A service from the Financial Times